Novel immunisation technology platform
We have developed KISIMA® (‘well’ in Swahili), our first-in-class proprietary immunisation technology platform. The peptide/protein-based vaccination technology is self-adjuvanting and enables the assembly of patented fusion molecules, all essential to generate potent immunity, into one single vaccine.
KISIMA® is highly versatile and we plan to develop vaccines for various cancer indications.
Powerful and highly versatile
KISIMA’s novel immunisation technology enables the assembly of all the components necessary for a potent anti-tumour immune response into one single therapeutic vaccine.
Thanks to this novel proprietary construct, the KISIMA® platform can uniquely and simultaneously provide all the parameters essential for an efficient therapeutic vaccine:
- Induce helper and cytotoxic T cells
- Promote immunological memory
- Target a broad patients population (different antigen and HLA restriction)
KISIMA® immunisation is shown to work in synergy with different immune checkpoint inhibitors in several tumour models.
KISIMA technology can be used to deliver:
- tumor-associated antigens
- neo-antigens
- modified epitopes
Amal Therapeutics SA
c/o Fondation pour Recherches Médicales
64 av. de la Roseraie
1205 Geneva
Switzerland
